On the one hand, knockout of SKP2 significantly increased the sensitivity of Her2 positive breast cancer cells to Herceptin [15], on the other hand, SKP2 silencing or inactivation can restore non-small cell lung cancer sensitivity to gefitinib treatment [16]. The gene discussed is SKP2; the disease is breast carcinoma.